[144] Revolution Medicines, Inc. SEC Filing

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) Form 144 summary: The filing notifies a proposed sale of 5,296 shares of common stock with an aggregate market value of $246,528.80. The company reports 186,933,190 shares outstanding. The shares to be sold were granted as restricted stock units on 03/01/2022 (1,232), 03/01/2023 (1,270), 03/01/2024 (1,632) and 03/01/2025 (1,162), each described as payment for services.

The filing also discloses past sales by the same person over the past three months totaling 129,289 shares for aggregate gross proceeds of $5,728,585.16. The listed broker for the proposed sale is ETRADE and the approximate sale date is 09/15/2025 on NASDAQ. The filer attests there is no undisclosed material adverse information.

Positive

• Transparent disclosure of acquisition dates and RSU grant amounts for all shares proposed to be sold
• Full reporting of recent open-market sales totaling 129,289 shares for $5,728,585.16, with broker and sale dates listed

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider RSU sales disclosed; recent dispositions total 129,289 shares for $5.73M, proposed sale small relative to outstanding shares.

The Form 144 documents both a proposed sale of 5,296 shares valued at $246,528.80 and multiple recent open-market dispositions by the same person. The historical sales over the reported period amount to 129,289 shares with gross proceeds of $5,728,585.16, indicating active monetization of vested RSUs. Relative to the issuer's reported outstanding shares (186,933,190), the volumes disclosed here represent a de minimis fraction of total equity, consistent with routine executive/employee liquidity events rather than a controlling shareholder exit.

Corporate Governance Expert

TL;DR: Filing shows compliance with Rule 144 disclosure requirements for insider sales and RSU-originated shares.

The notice itemizes acquisition dates and grant nature for each block of securities (restricted stock unit grants dated 03/01/2022, 03/01/2023, 03/01/2024, 03/01/2025) and lists the broker and planned sale date, which supports transparent compliance with disclosure rules. The filer signs the required attestation about lack of undisclosed material adverse information; no plan-adoption date for a 10b5-1 plan is provided in the form content.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE Financial Corporation 3 Edison Drive Alpharetta GA 30005	5296	246528.80	186933190	09/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/01/2022	Restricted stock unit grant	Issuer			1232	03/01/2022	Services rendered
Common Stock	03/01/2023	Restricted stock unit grant	Issuer			1270	03/01/2023	Services rendered
Common Stock	03/01/2024	Restricted stock unit grant	Issuer			1632	03/01/2024	Services rendered
Common Stock	03/01/2025	Restricted stock unit grant	Issuer			1162	03/01/2025	Services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Stephen Michael Kelsey c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	06/16/2025	4289	170830.87
Stephen Michael Kelsey c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	09/11/2025	44059	1919963.45
Stephen Michael Kelsey c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	09/11/2025	55941	2488518.60
Stephen Michael Kelsey c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	09/15/2025	23682	1087418.24
Stephen Michael Kelsey c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	09/15/2025	1318	61854.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many shares does the filer propose to sell in the Form 144 for RVMD?

The filer proposes to sell 5,296 shares of common stock with an aggregate market value of $246,528.80.

What broker and exchange are listed for the proposed sale of RVMD shares?

The broker listed is ETRADE Financial Corporation and the approximate sale date is 09/15/2025 on NASDAQ.

What is the total of the filer’s recent sales disclosed in the filing?

The filing shows recent sales totaling 129,289 shares for aggregate gross proceeds of $5,728,585.16.

What is the origin of the securities being sold according to the filing?

All securities to be sold were acquired as restricted stock unit grants from the issuer, listed with grant dates from 03/01/2022 through 03/01/2025.

How many shares outstanding does the filing report for RVMD?

The filing reports 186,933,190 shares outstanding.